Objective To investigate the clinical efficacy of Guanxinning tablets combined with conventional Western medicine in elderly patients with coronary heart disease (CHD) complicated by chronic heart failure (CHF) of heart-blood stasis obstruction type. Methods A randomized controlled trial was conducted. A total of 60 elderly patients with CHD and CHF of heart-blood stasis obstruction type who met the inclusion and exclusion criteria were enrolled from December 2024 to October 2025 and randomly assigned to a control group and a treatment group, with 30 cases in each group. The control group received conventional Western medicine treatment, including antiplatelet, lipid-lowering, cardiotonic, diuretic, and vasodilator agents. The treatment group received Guanxinning tablets in addition to conventional Western medicine treatment. After 3 months of treatment, the two groups were compared in terms of traditional Chinese medicine (TCM) syndrome score, serum albumin (Alb), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), 6-minute walk test (6MWT), clinical efficacy, and adverse reactions occurring during the treatment. Results After 3 months of continuous treatment, the treatment group showed a greater decrease in TCM syndrome score (P<0.05); Alb level increased significantly (P<0.05); TC, LDL-C, and TG decreased significantly (all P<0.05); BNP levels decreased and LVEF increased (both P<0.05); 6MWT distance increased and the overall effective rate of clinical efficacy was 93.33% (P<0.05). In addition, the incidence of adverse reactions in the treatment group was 3.33%, which was significantly lower than 20.00% in the control group (P<0.05). Conclusion Guanxinning tablets combined with conventional Western medicine has significant clinical efficacy in the treatment of elderly patients with CHD and CHF of heart-blood stasis obstruction type. It can effectively improve cardiac function, TCM syndrome score, nutritional metabolism, and blood lipid levels, enhance exercise tolerance, and has good safety with fewer adverse reactions.
Key words
Guanxinning tablets /
coronary heart disease /
chronic heart failure /
randomized controlled trial
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] TAYLOR RS, DALAL HM, MCDONAGH STJ.The role of cardiac rehabilitation in improving cardiovascular outcomes[J]. Nat Rev Cardiol, 2022, 19(3): 180-194.
[2] YAN Q, CHEN X, YU C, et al.Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis[J]. BMC Cardiovasc Disord, 2024, 24(1): 1-10.
[3] 王雅琴, 张艳, 张伟. 冠心舒通胶囊治疗心血瘀阻型冠心病心力衰竭的临床疗效[J]. 中国实验方剂学杂志, 2023, 29(7): 153-159.
[4] 李静, 郭志华, 刘建和, 等. 血府逐瘀汤对冠心病心血瘀阻证模型大鼠血管新生因子的影响[J]. 时珍国医国药, 2024, 35(4): 822-826.
[5] SKI CF, TAYLOR RS, MCGUIGAN K, et al. Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation[J]. Cochrane Database Syst Rev, 2024, 4(4): CD013508.
[6] MASINI G, GRAHAM FJ, PELLICORI P, et al.Criteria for iron deficiency in patients with heart failure[J]. J Am Coll Cardiol, 2022, 79(4): 341-351.
[7] 李静, 郭志华, 刘建和, 等. 冠心病心血瘀阻证模型大鼠的建立及方药评价[J]. 中药药理与临床, 2024, 40(1): 86-93.
[8] TAKAHASHI T, IWATA K, MORISAWA T, et al.Incidence of hospitalization-associated disability in older patients with heart failure[J]. Circ J, 2024, 88(5): 672-679.
[9] ROCCO IS, MATOS-GARCIA BC, VICECONTE M, et al.Six-minute walk test reveals delayed oxygen uptake kinetics in ischemic cardiomyopathy[J]. Braz J Med Biol Res, 2025, 58: e14276.
[10] 刘玉峰, 王敬民, 于占文, 等. 基于运动心肺功能试验评估神香苏合丸治疗稳定型心绞痛寒凝心脉证患者临床疗效的研究[J]. 重庆医学, 2023, 52(1): 26-29.
[11] YANG Y, LI X, CHEN G, et al.Traditional Chinese medicine compound and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI randomized clinical trial[J]. JAMA, 2023, 330(16): 1534-1545.
[12] MIN Q, WU Z, YAO J, et al.Association between atherogenic index of plasma control level and incident cardiovascular disease in middle-aged and elderly Chinese individuals with abnormal glucose metabolism[J]. Cardiovasc Diabetol, 2024, 23(1): 54.
[13] QU C, LIAO S, ZHANG J, et al.Burden of cardiovascular disease among elderly: based on the global burden of disease study 2019[J]. Eur Heart J Qual Care Clin Outcomes, 2024, 10(2): 143-153.
[14] WANG Y, CUI H, LI L, et al.Digitalization of prevention and treatment and the combination of western and Chinese medicine in management of acute heart failure[J]. Front Cardiovasc Med, 2023, 10: 1146941.
[15] 向会, 陆萍, 郑巍, 等. 冠心宁片对冠心病血瘀证氯吡格雷抵抗的调节作用分析[J]. 解放军药学学报, 2024, 37(3): 251-254.
[16] GONG D, YUAN T, WANG R, et al.Network pharmacology approach and experimental verification of Dan-Shen decoction in the treatment of ischemic heart disease[J]. Pharm Biol, 2023, 61(1): 69-79.
[17] LIU C, GUO X, WANG H, et al.Combination of Qi benefiting and blood circulation promoting herbs with dapagliflozin in the treatment of type 2 diabetes mellitus combined with heart failure: asystematic evaluation and meta-analysis based on a randomized controlled trial[J]. Complement Med Res, 2024, 31(6): 551-566.
[18] TONG R, WU T, CHEN J.Chinese medicine supplementing Qi and activating blood circulation relieves the progression of diabetic cardiomyopathy[J]. Endocr Metab Immune Disord Drug Targets, 2024, 24(1): 163-171.
[19] CAO L, NI H, GONG X, et al.Chinese herbal medicines for coronary heart disease: clinical evidence, pharmacological mechanisms, and the interaction with gut microbiota[J]. Drugs, 2024, 84(2): 179-202.
[20] EROGLU H, METIN ZG.Correlation between symptom status, health perception, and spiritual well‐being in heart failure patients: a structural equation modeling approach[J]. J Nurs Scholarsh, 2024, 56(4): 490-506.